No Data
Insider Sale: Director David Guyer Sells Shares of EyePoint Pharmaceuticals Inc (EYPT)
EyePoint Pharmaceuticals(EYPT.US) Director Sells US$147.04K in Common Stock
$EyePoint Pharmaceuticals(EYPT.US)$ Director GUYER DAVID R sold 11,625 shares of common stock on May 14, 2024 at an average price of $12.649 for a total value of $147.04K.Source: Announcement What is
Maintained Buy Rating on EyePoint Pharmaceuticals Amid Positive Outlook for EYP-1901 in Wet AMD
Analyst Graig Suvannavejh of Mizuho Securities reiterated a Buy rating on EyePoint Pharmaceuticals (EYPT – Research Report), retaining the price target of $30.00.
Crocs To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.Jefferies c
EyePoint Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
EyePoint Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. : The EyePoint Pharmaceuticals (EYPT.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $33.00 to $30.00.
HC Wainwright & Co. : The EyePoint Pharmaceuticals (EYPT.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $33.00 to $30.00.